AA thesis manuscript Tofacitinib vs methotrexate

My research hypothesis is that methotrexate is non-inferior to tofacitinib in treating moderate to severe alopecia areata. In our research, we evaluated the SALT score, Scalp hair assessment PRO score at every month, and DLQI, and PHQ scores at baseline, at 6 months and 9 months of study period. we also evaluated side effects of both drugs at each visit.本研究的研究假设为：甲氨蝶呤（methotrexate）治疗中重度斑秃（alopecia areata）的疗效非劣于托法替布（tofacitinib）。本研究中，我们于每月随访时评估SALT评分（SALT score）与头皮毛发评估患者报告结局（Patient Reported Outcome, PRO）评分，并于研究周期的基线、6个月及9个月时评估皮肤病生活质量指数（Dermatology Life Quality Index, DLQI）与患者健康问卷（Patient Health Questionnaire, PHQ）评分。此外，我们于每次就诊时评估两种药物的不良反应。